Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
William H. Miller III Living Trust dated April 17, 2017 filed a Schedule 13G reporting beneficial ownership of 34,051,925 shares of Precigen, Inc. common stock, representing 9.2% of the class as presented in the filing. The reported amount includes 16,666,667 shares that the reporting person could acquire within 60 days upon exercise of warrants. The filing states the reporting person has sole voting and sole dispositive power over the reported shares.
The percent calculation in the filing is based on 298,455,084 shares outstanding plus an additional 54,937,411 shares delivered upon conversion of preferred stock and the 16,666,667 warrant shares referenced above. The trust certified the holdings are not intended to influence control of the issuer.
Randal J. Kirk and related entities updated their Schedule 13D/A for Precigen, Inc. (PGEN). The filing discloses that on September 17, 2025 the R.J. Kirk Declaration of Trust converted 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock into 17,385,257 shares of Common Stock. Between September 18–19, 2025, Kapital Joe, LLC (under common control) sold 5,000,252 shares in open-market transactions for approximately $18,648,905.62. The cover-page holdings show Mr. Kirk with beneficial ownership of 146,295,359 shares (39.4%), RJ DOT 98,831,434 shares (26.6%), Sunset 2020 LLC 16,406,828 shares (4.4%), and Third Security, LLC 27,454,284 shares (7.4%). The filing also notes exercisable warrants (16,666,667) and options (906,512) included in Mr. Kirk's beneficial ownership calculation and incorporates prior amendments.
Randal J. Kirk, a director and 10% owner of Precigen, Inc. (PGEN), reported multiple transactions in mid-September 2025. On 09/17/2025 the reporting person received 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock sold in a private placement, convertible into 17,385,257 common shares at a conversion mechanism described in the agreement. On 09/18/2025 and 09/19/2025 the reporting person (through entities he controls) sold a total of 5,000,252 common shares: 1,403,360 shares at a weighted average price of $3.86 and 3,596,892 shares at a weighted average price of $3.68. The filing lists multiple entities controlled by Mr. Kirk that hold beneficial ownership interests and disclaims direct beneficial ownership except for pecuniary interest.
Precigen, Inc. (PGEN) Form 144 notifies the market of a proposed sale of 252 common shares on Nasdaq with an aggregate market value of $970, against 297,972,920 shares outstanding. The filer reports acquiring 3,112,507 shares on 07/03/2018 in a public offering for cash.
The filing also discloses that Kapital Joe, LLC (Randal J. Kirk as agent) sold 1,403,360 common shares on 09/18/2025 for gross proceeds of $5,422,348. The signer certifies no undisclosed material adverse information and attests to the accuracy of the notice.
Precigen, Inc. (PGEN) filed a Form 144 notice reporting a proposed sale of 5,000,000 common shares with an aggregate market value of $19,625,000. The filing lists the broker as Charles Schwab Corp and names Nasdaq as the exchange, with an approximate sale date of 09/18/2025. The filing discloses the acquisition history for the shares being sold, showing multiple purchases and initial/public offerings between 2013 and 2018 that total the lots listed. The filer reports 297,972,920 shares outstanding, and notes there were no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Precigen, Inc. reported that on September 15, 2025, holders of its 8.00% Series A Convertible Perpetual Preferred Stock converted 79,000 preferred shares, with an aggregate stated value of
The exchange was conducted with existing security holders and relied on the exemption from registration in Section 3(a)(9) of the Securities Act of 1933, with no commission or other remuneration paid for soliciting the exchange.
Helen Sabzevari, President and CEO and a director of Precigen, Inc. (PGEN), reported the vesting of performance stock units. On 09/12/2025, the second installment of PSUs granted August 28, 2024 vested, resulting in 825,000 shares of common stock being issued or payable in cash equivalent value. The filing lists the shares as directly owned following the transaction. The Form 4 was signed on behalf of Ms. Sabzevari by an attorney-in-fact and filed on 09/16/2025. The document states each PSU converts to one share or an equivalent cash amount.
Harry Thomasian Jr., Chief Financial Officer of Precigen, Inc. (PGEN), reported the vesting of 125,000 performance stock units (PSUs) on 09/12/2025. These PSUs were part of a grant made on August 28, 2024; the filing states the second installment vested after meeting the applicable performance condition. Each PSU may be settled in one share of the company’s common stock or an equivalent cash amount. Following the reported transaction, Mr. Thomasian directly beneficially owns 125,000 shares attributable to these vested PSUs. The Form 4 was signed on 09/16/2025.
Donald P. Lehr, Chief Legal Officer of Precigen, Inc. (PGEN), reported the vesting of 54,000 performance stock units (PSUs) on 09/12/2025. The filing shows those PSUs converted into 54,000 shares of the issuer's common stock (or an equivalent cash amount) at a reported price of $0, resulting in direct beneficial ownership of 54,000 shares following the transaction. The PSUs represent the second installment of an award originally granted on August 28, 2024 and vested based on achievement of the applicable performance condition for that installment. The form is signed by Mr. Lehr on 09/16/2025.
Phil Tennant, Precigen Chief Commercial Officer, reported the vesting of 25,000 performance stock units (PSUs) on 09/12/2025 that converted to common stock. The Form 4 shows these PSUs were part of an award originally granted August 28, 2024 and represent the second installment that vested after achievement of the applicable performance condition. Each PSU is payable in one share of the issuer's common stock or a cash equivalent. Following the reported transaction, Mr. Tennant beneficially owns 25,000 shares of Precigen common stock. The Form 4 was signed by attorney-in-fact Donald P. Lehr on 09/16/2025.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
